Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Risk management programs and reimportation

Executive Summary

FDA shares concerns about the potential for reimportation to circumvent the distribution program set up for RU-486, McClellan says, but concern extends to all drugs covered by risk management programs. "This is a general concern about the safety of drugs that are imported that we don't regulate." During House debate on reimportation, PhRMA suggested to pro-life groups that they may have a stake in the vote based on the potential that the bill would ease access to RU-486 (1"The Pink Sheet" July 28, 2003, p. 13)...

You may also be interested in...

Rx Reimportation Passes House; CBO Score May Keep It Out Of Medicare Rx

The Congressional Budget Office's determination that prescription drug reimportation would not provide any cost savings could help House/Senate Medicare conferees distance themselves from the House's positive vote on reimportation

Can RFID Tags Give Generics Companies An Edge?

Fresenius Kabi’s decision to add radio frequency-identification (RFID) tags to 24 products used in hospital operating rooms will help the company’s hospital pharmacy customers reduce waste, increase efficiencies and facilitate tighter medication inventory control, executives claim. However, only 10% of US hospitals are currently equipped to scan and process RFID tags, despite larger adoption rates in other industry sectors. COVID-19-related revenue losses may push more hospitals to adopt automated RFID medication management systems to save time and reduce labor costs.

Bankruptcy Court Gives Green Light To Akorn Sale

Just three years after Fresenius Kabi agreed a $4.75bn takeover of the US injectables specialist, Akorn has obtained approval from a US bankruptcy court for its sale to the company’s existing lenders, having filed for Chapter 11 bankruptcy earlier this year.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts